CIBC Private Wealth Group
RVNC

CIBC Private Wealth Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

CIBC Private Wealth Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-39
Closed -$132 – 3307
2024
Q4 		$132 Sell
39
-100
-72% -$436 ﹤0.01% 2905
2024
Q3 		$721 Hold
139
– – ﹤0.01% 2943
2024
Q2 		$388 Sell
139
-4,655
-97% -$15.9K ﹤0.01% 3005
2024
Q1 		$22.7K Buy
+4,794
New +$28.4K ﹤0.01% 2002

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

CIBC Private Wealth Group's RVNC Position: Q1 2025 in Review

CIBC Private Wealth Group sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 39 shares — an estimated $132 sold.

CIBC Private Wealth Group first reported a position in RVNC in Q1 2024 and held it in 4 quarters. The position peaked at $22.7K in Q1 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • CIBC Private Wealth Group reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • CIBC Private Wealth Group sold 39 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $132.
  • CIBC Private Wealth Group first reported a position in Revance Therapeutics, Inc. in Q1 2024 and held it in 4 quarters.
  • CIBC Private Wealth Group's Revance Therapeutics, Inc. position peaked at $22.7K in Q1 2024.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on CIBC Private Wealth Group's 13F filing for Q1 2025, filed 14 May 2025.